Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ

Research site

(Unclaimed)

Location

4550 East Bell Road Suite 170, Phoenix, Arizona, United States of America

Site insights

Top conditions

Top treatments

Baricitinib

Methotrexate

Ixekizumab

Vedolizumab

Iloprost

Upadacitinib

Adalimumab

Mirikizumab

BIIB059

Litifilimab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 30 total trials

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE)....

Enrolling

Subacute Cutaneous Lupus Erythematosus

Chronic Cutaneous Lupus Erythematosus

Drug: Litifilimab

Drug: Placebo

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Active, not recruiting

Crohn's Disease

Drug: Mirikizumab

Locations recently updated

A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST LTE)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE)....

Invitation-only

Subacute Cutaneous Lupus Erythematosus

Chronic Cutaneous Lupus Erythematosus

Drug: BIIB059 (litifilimab)

A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease (INDIGO)

This study aims to examine the efficacy and safety of obexelimab for the prevention of flare of IgG4-related disease (IgG4-RD)

Active, not recruiting

IgG4 Related Disease

Other: Placebo

Drug: Obexelimab

A Study of CDPATH™ to Help Manage and Treat Crohn's Disease (COMPASS-CD)

CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. Th...

Active, not recruiting

Crohn's Disease

Other: Blood Draw

Other: CDPATH™

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Enrolling

Systemic Lupus Erythematosus

Drug: Upadacitinib

Drug: Placebo